Amplifon Reports 4.7% Organic Growth in Second Quarter of 2026

MILAN, ITALY — Amplifon, the parent company of Miracle Ear, reported accelerating organic revenue growth and improved profitability in the second quarter of 2026, with positive organic performance across Europe, the Americas, and Asia Pacific.

According to a press release from the company, second-quarter revenue totaled €606.0 million (≈US$696.9 million), an increase of 2.2% at current exchange rates and 1.7% at constant exchange rates compared with the same period last year. Organic growth reached 4.7%, its highest level in two years, while acquisitions contributed another 0.5%. 

The company’s Fit4Growth efficiency program reduced second-quarter revenue by 3.5%. Amplifon attributed the impact primarily to the closure of more than 200 clinics since the program began, the divestiture of its UK business, and the termination of a managed care agreement in the United States.

Adjusted EBITDA rose 6.1% to €156.2 million (US$179.6 million), with the adjusted EBITDA margin increasing 90 basis points to 25.8%. Adjusted EBIT increased 11.9% to €92.3 million (US$106.1 million), while adjusted net profit climbed 17.1% to €57.2 million (US$65.8 million). 

For the first half of 2026, Amplifon generated revenue of €1.186 billion (US$1.364 billion), up 1.3% at constant exchange rates and 0.4% at current exchange rates. Organic growth was 3.5%.

First-half adjusted EBITDA increased 3.6% to €298.0 million (US$342.7 million), with the margin improving 70 basis points to 25.1%. Adjusted net profit rose 12.3% to €101.6 million (US$116.8 million). Adjusted free cash flow reached €68.0 million (US$78.2 million), 70% higher than in the first half of 2025. 

“In the second quarter, we delivered excellent results, achieving our highest organic growth in the past two years, outperforming the market across all geographies and significantly improving profitability,” said Amplifon CEO Enrico Vita in the press statement. “These results confirm the effectiveness of the many initiatives and investments undertaken in 2025, which are now delivering tangible outcomes and further strengthening our competitive position…The very positive results achieved in the first half, together with the solid start to the third quarter, reinforce our confidence in the outlook for the full year 2026.”

As reported by HearingTracker in March, Amplifon has announced plans to acquire GN Hearing in a US$2.64 billion deal that could reshape the global hearing care and hearing aid market. The deal is expected to close by year’s end. (For more information about the deal, see HT’s interview with GN CEO Peter Karlströmer.)

Organic growth during the second quarter reached 4.5% in Europe, the Middle East, and Africa; 6.0% in the Americas; and 4.3% in Asia Pacific. Amplifon reports its US business benefited from strong private-pay performance, which more than offset contraction in the insurance segment. Australia, China, and Southern Europe were also highlighted as strong-performing markets.